Abstract:Background Cancer vaccines are able to achieve tumor-specific immune editing in early-phase clinical trials. However, the infiltration of cytotoxic T cells into immune-deserted tumors is still a major limiting factor. An optimized vaccine approach to induce antigen-specific T cells that can perform robust tumor infiltration is important to accelerate their clinical translation. We previously developed a STING-activating PC7A nanovaccine that produces a strong anti-tumor T cell response on subcutaneous injection. This study systematically investigated the impact of administration methods on the performance of nanovaccines. Methods Tumor growth inhibition by intratumoral delivery and subcutaneous delivery of nanovaccine was investigated in TC-1 human papillomavirus-induced cancer model and B16-OVA melanoma model. Nanovaccine distribution in vivo was detected by clinical camera imaging, systemic T cell activation and tumor infiltration were tested by in vivo cytotoxicity killing assay and flow cytometry. For mechanism analysis, T cell recruitment was investigated by in vivo migration blocking assay, multiplex chemokine array, flow cytometry, RT-qPCR, chemotaxis assay and gene knockout mice. Results Nanovaccine administration was found to alter T cell production and infiltration in tumors. Intratumoral delivery of nanovaccines displayed superior antitumor effects in multiple tumor models compared with subcutaneous delivery. Mechanistic investigation revealed that intratumoral administration of the nanovaccine significantly increased the infiltration of antigen-specific T cells in TC-1 tumors, despite the lower systemic levels of T cells compared with subcutaneous injection. The inhibition of tumor growth by nanovaccines is primarily dependent on CD8 + cytotoxic T cells. Nanovaccine accumulation in tumors upregulates CXCL9 expression in myeloid cells in a STING dependent manner, leading to increased recruitment of IFNγ-expressing CD8 + T cells from the periphery, and IFNγ reciprocally stimulates CXCL9 expression in myeloid cells, resulting in positive feedback between myeloid-CXCL9 and T cell-IFNγ to promote T cell recruitment. However, the STING agonist alone could not sustain this effect in the presence of a systemic deficiency in antigen-specific T cells. Conclusions Our results demonstrate that intratumoral administration of PC7A nanovaccine achieved stronger antitumor immunity and efficacy over subcutaneous injection. These data suggest intratumoral administration should be included in the therapeutic design in the clinical use of nanovaccine.

A "trained immunity" inducer-adjuvanted nanovaccine reverses the growth of established tumors in mice

Gold Nanocage-Based Photothermal Ablation Facilitates in Situ Vaccination for Melanoma Therapy.

Exploiting Immunostimulatory Mechanisms of Immunogenic Cell Death to Develop Membrane-Encapsulated Nanoparticles As a Potent Tumor Vaccine.

Nanovaccine Showing Potent Immunotherapy to Tumor by Activating Γδ T Cells

Nanovaccines integrating endogenous antigens and pathogenic adjuvants elicit potent antitumor immunity

Robust Anti‐Tumor T Cell Response with Efficient Intratumoral Infiltration by Nanodisc Cancer Immunotherapy

Tumor Antigen Loaded Nanovaccine Induced NIR‐Activated Inflammation for Enhanced Antigen Presentation During Immunotherapy of Tumors

Two-pronged anti-cancer nanovaccines enpowered by exogenous/endogenous tumor-associated antigens

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Nanovaccine’s rapid induction of anti-tumor immunity significantly improves malignant cancer immunotherapy

Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality

Outer Membrane Vesicle‐Based Nanohybrids Target Tumor‐Associated Macrophages to Enhance Trained Immunity‐Related Vaccine‐Generated Antitumor Activity

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy

Tumor‐Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano‐Vaccine for Overcoming Immune Barriers for Effective and Long‐Term Cancer Immunotherapy

Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine

Uplifting Antitumor Immunotherapy with Lymph-Node-Targeted and Ratio-Controlled Codelivery of Tumor Cell Lysate and Adjuvant

Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger

Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor

Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity

Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination

Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells